Project Grant R41DK126520

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $673,379 to Rise Therapeutics LLC to develop a novel synthetic biology-based cellular medicine for treating ulcerative colitis. The goal is to engineer a Lactococcus lactis probiotic strain that can deliver the anti-inflammatory protein SLPA to modulate immune responses, strengthen the...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $315,270 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to establish a new therapeutic strategy for inflammatory bowel disease (IBD) treatment. The project will leverage the role of cholinergic innervation in mediating intestinal inflammation by using optogenetic activation of enteric cholinergic neurons...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,078,081 to Orphagen Pharmaceuticals, Inc. to develop a novel class of small molecule antagonists that inhibit the gut migration of activated T cells. The goal is to explore this as a promising therapeutic approach for inflammatory bowel disease (IBD), which affects up to 70% of...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is supporting research into the role of the extracellular signaling protein Reelin and its potential therapeutic applications for Fragile X Syndrome (FXS). The $187,500.00 award, with a performance period from January 3, 2025 to December 31, 2026, is being provided to the...

This $919,404 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of QR401 - a first-in-class, oral, antigen-presenting cell (APC)-specific AMPK pathway agonist nanomedicine for the treatment of inflammatory bowel disease (IBD). The funding will enable Qrono, Inc., a for-profit R&D company, to prepare and...

This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $253,250 to HMH Hospitals Corporation, a non-profit healthcare organization, for research on celiac disease and inflammatory bowel diseases. The key products and services to be delivered under this 5-year award include: Generating whole-genome bisulfite sequencing data (methyl-seq) from key cell types, with a major focus on intestinal...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $252,152 to the Benaroya Research Institute at Virginia Mason to characterize circulating and visceral T cells specific for the autoantigen integrin αvβ6 in ulcerative colitis. The research aims to adapt the Activation Induced Marker (AIM) assay to evaluate T cells from mesenteric lymph nodes and colon samples of...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $664,163 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Icahn School of Medicine at Mount Sinai. The project aims to investigate the regulation of CD39 expression in gamma delta intraepithelial lymphocytes (GD IELs) and its influence on GD IEL function and metabolism in the context of inflammatory bowel disease (IBD). The research will...

This $151,808 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate the role of the neuropeptide adrenomedullin 2 (ADM2) in regulating intestinal inflammation and tissue protection. The project, conducted by Weill Medical College of Cornell University, aims to generate a detailed understanding of how the ADM2-ADM2 receptor...

This $811,752 project grant from the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases will fund research at Hawaii Pacific University exploring the relationship between claudin protein expression and mucus barrier function in inflammatory bowel diseases. Principal Investigator Dr. Capaldo will test the hypothesis that inflammatory cytokines disrupt ion and fluid homeostasis in the colon through aberrant claudin expression, weakening the mucus barrier...